FDA issues draft guidance on appeals process

FDA issues draft guidance on appeals process

The FDA today released draft guidance clarifying existing recommendations for how medical device manufacturers can appeal the federal watchdog agency’s decisions on marketing applications.

The draft guidance, which the FDA is asking industry to comment on over the next 90 days, pertains to requests for documentation of rationales for significant decisions and requests for supervisory review of regulatory decisions and actions taken by the FDA’s Center for Devices & Radiological Health.

The draft defines what a "significant decision" is, something that was previously not specified. Significant decisions are now restricted to 510(k): not substantially equivalent or substantially equivalent; PMA/HDE: not approvable or approvable with conditions; approval IDE: disapproval or approval; or
failure to reach agreement on a protocol.

The agency does not believe that actions earlier in the review process constitute "significant decisions." Thus, the FDA is not required to respond to appeals to any of the following: Refusals to accept/file, requests for additional information, or deficiency letters during the review of a premarket submission.

The FD&C Act requires the FDA to provide, upon request of a person who is seeking to submit or who has submitted a 510(k), PMA, IDE, or HDE, a "substantive summary" of the scientific and regulatory rationale for any significant decision regarding the submission, including documentation of significant controversies or differences of opinion and the resolution thereof, the draft guidance stated.

For example, anyone who submits a 510(k) receives either a substantially equivalent or not substantially equivalent decision from CDRH. The submitter may then request, and CDRH must provide, a substantive summary of the rationale for the decision.

According to the draft guidance, the substantive summary may be the final version of the review memorandum by the lead reviewer or another summary document that includes the following elements: an explanation of the rationale for the regulatory decision; documentation of significant controversies or differences of opinion, i.e., ones the 
resolution of which had a direct bearing on the regulatory decision; and, references to published literature and consensus standards upon which the decision-maker relied. 


In addition, the draft guidance spells out timeframes for the appeals process. Device marketing applicants are entitled to request a supervisory review of the significant decision made with regard to their device application within 30 days of the decision, in which they must indicate whether they want an in-person meeting or a teleconference review, according to the federal watchdog.

The FDA then has 30 days to respond to the request, and has 45 days after the initial request is made to issue a decision. In cases where an in-person meeting or teleconference has been requested, the agency has up to 30 days after such meeting or teleconference to issue a decision.

The draft guidance noted that these timeframes do not apply in cases that are referred to experts outside of the FDA.

Also, the review may be conducted at the next supervisory level or higher above the individual who made the significant decision, the FDA stated.

Additionally, the draft guidance clarifies that the FDA will only provide these summaries to the owner of any proprietary information, so there should be no need to withhold trade secret or confidential commercial information or any other information in the summary.

Anyone other than the device owner (generally the device sponsor or manufacturer) would need to file a FOIA request to obtain an executive summary of a significant decision. The FDA clarifies that it would withhold trade secret and confidential commercial information, but is not required to withhold any other information.

The agency noted that it developed this draft guidance as a companion to its current appeals guidance. When finalized, the agency intends to include the questions and answers in this draft guidance as an appendix to the appeals guidance.

RSS From Medical Design & Outsourcing

  • GlobTek presents its latest level VI AC/DC adapter and connverter
    T-43086-WWVV-X.X-Q Model is an addition to GlobTek’s Level VI compliant GT-43086 family and represents GlobTek’s 6 Watt wall plug-in series of AC/DC adapters (power supplies and chargers) with International Interchangeable blades. GlobTek’s changeable input blade system with individual field replaceable input plugs, including: North America and Japan NEMA 1-15P, Australian, UK BS 1363, European CEE […]
  • Sanmina’s familiarity with FDA gets skin treatment product to market fast
    The medical market for cosmetic devices is booming. However, quickly launching new products to meet demand is becoming more challenging because device manufactures face increased regulatory scrutiny. To help meet regulatory requirements, aesthetic and other medical-device OEMs are partnering with electronics manufacturing services (EMS) companies that also offer expertise with the FDA filings necessary to […]
  • Fluid connectors and quick disconnects for IVD equipment from CPC
    Colder Products Company (CPC) offers thousands of tubing connectors, quick disconnects and fittings for smart fluid handling in IVD and analytical equipment. Non-spill connectors speed testing throughput by eliminating drips, preventing air inclusion and increasing operator safety. Panel mount connectors can be added to existing equipment or bottle caps to provide secure, leak-free connections. Puncture […]
  • 310 Watt desktop medical power supply meets efficiency level VI requirements
    Power Partners releases a new 310 Watt medical grade desktop power supply from their PEAMD Series of AC and DC adapters. The 310 Watt unit is packed for ideal performance inside a compact case measuring 7.8 x 4 x 2 in. with a weight of only 3 lbs. The PEAMD310 Series is approved to the latest […]
  • Saelig introduces Multiple Instrument System MIS4 universal test system
    Saelig Company has introduced the ABI Electronics’ Multiple Instrument Station MIS4, an all-in-one testing tool that provides all commonly required test instruments in one compact programmable hardware module, mounted in a compact case or installed in a PC-drive bay. Controlled by ABI’s sophisticated SYSTEM 8 Ultimate PC software with a simple yet programmable operator interface, […]
  • AssurX announces document management software update for small to mid-size companies in FDA regulated industries
    AssurX, an enterprise quality management, risk and regulatory compliance solution provider, announces the release of the latest update to their AssurX document management software. The document management solution provides a cost-effective solution for small to medium sized companies faced with streamlined operations and is fully compliant for FDA regulated industries. Ideal solution for small to […]
  • Saelig presents new Amplicon Impact-R 1100F series computer
    Saelig Company announces the Amplicon Impact-R 1100F series, a fanless system powered by the Intel ATOM D2550 processor. Configured with a high performance 2.5 in. MLC Solid State Drive (SSD), the Impact-R 1100F series is a silent controller system. With options for multiple serial communication ports, the Impact-R 1100F can offer up seven DB9 connections […]
  • Gerresheimer to acquire Centor
    Gerresheimer AG, a partner to the global pharmacy and healthcare industry, will further extend its pharmaceutical packaging business with the acquisition of Centor. Gerresheimer has reached an agreement with Nemera Development S.A. to acquire 100% of the share capital of Centor US Holding. “Centor is the highly profitable market leader for plastic vials and closures in […]
  • Methods Machine Tools presents the new Nakamura-Tome NTRX-300
    Methods Machine Tools, a developer of precision machine tools and automation, has introduced the new Nakamura-Tome NTRX-300, a multitasking turning center featuring complete parts machining in one operation, with a built-in load and unload automation system and advanced operator recognition management software. The NTRX-300 features true opposing twin spindles: an 8 in. A2-6 25 HP or […]
  • MSC Apex Diamond Python and Smart Midsurface speeds modeling to validation
    MSC Software announced a new release of MSC Apex, the company’s award-winning next generation Computer Aided Engineering (CAE) platform. The MSC Apex Diamond Python release introduces: · The fourth release of MSC Apex Modeler is a CAE Specific direct modeling and meshing solution that streamlines CAD clean-up, simplification and meshing workflow. New in this release is […]
  • Quality Metrics: FDA’s plan for a key set of measurements to help ensure manufacturers are producing quality medications
    Editor’s Note: This article is written by Ashley Boam and Mary Malarkey from the “FDA Voice” blog. Boam is an FDA’s acting Director of the Office of Policy for Pharmaceutical Quality, the Office of Pharmaceutical Quality and the Center for Drug Evaluation and Research. Malarkey is an FDA’s Director if the Office of Compliance and Biologics Quality […]

Leave a Reply